Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and distribution strategy.
|Articles|June 30, 2011
- Pharmaceutical Commerce - May/June 2011
Intro
Advertisement
Biopharma Cold Chain 2011 Sourcebook
The Biopharma Cold Chain 2011 Sourcebook is a comprehensive business guide to the world’s supply chain for temperature-sensitive drugs and biologics. The updated 2011 edition provides an assessment and forecast of cold-chain logistics spending worldwide, and a detailed and up-to-date analysis of regulatory, market, technological and business developments that are expanding the demand for temperature-assured storage and transportation and improving the supply chain’s ability to deliver that assurance.
By Mark Lipowicz and Nicholas Basta, Pharmaceutical Commerce
and Editorial Adviser: Rafik Bishara, PhD, Pharmaceutical Cold Chain Interest Group
Articles in this issue
over 15 years ago
What Makes a Pharmaceutical Industry Leader?over 15 years ago
How REMS Affect Pharmaceutical Distribution Processes and Partnersover 15 years ago
Patient-Administered Therapies Drive New Delivery System Designsover 15 years ago
For a Lucky Few, Biopharma Expansion a Reality Againover 15 years ago
Making Pallets a Supply Chain Asset Instead of an Unrecoverable CostAdvertisement
Related to this article
A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.
Generative AI has made pharma teams faster, but real value depends on redesigning commercialization workflows, especially as agentic AI raises the governance stakes.
Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.
Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient support leaders by company size and therapeutic area.
Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.
Accessia Health’s Tiara Green says Part D reforms eased drug costs, but premiums, deductibles and payer policies still limit patient access.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How CMS’ Final Negotiation Rule Treats New Drug Formulations
2
Report: 2026 Patient Support Awards Name Leaders in Large, Small Pharma
3
Big Three Distributors Lean on Specialty for Profit Growth
4
ELPRO CEO on How Biologics Raised the Stakes in Cold Chain Handling
5